| Mar'20 | Dec'19 | Sep'19 | Jun'19 | Mar'19 | Sep'18 | Jun'18 |
|---|---|---|---|---|---|---|
Revenue | ||||||
Total revenue | ||||||
20,910 | 24,209 | 26,058 | 22,138 | 12,666 | 17,188 | 11,568 |
Operating expenses | ||||||
Cost of revenue | ||||||
5,343 | 5,951 | 5,601 | 5,734 | 4,988 | 5,360 | 5,044 |
Research and development | ||||||
23,935 | 21,189 | 20,506 | 16,527 | 12,483 | 9,783 | 9,452 |
Sales and marketing | ||||||
14,007 | 12,640 | 9,099 | 8,897 | 7,817 | 6,039 | 5,329 |
General and administrative | ||||||
11,821 | 8,189 | 8,477 | 6,662 | 7,004 | 4,739 | 4,632 |
Amortization of intangible assets | ||||||
424 | 428 | 428 | 423 | 419 | 428 | 424 |
Total operating expenses | ||||||
55,530 | 48,397 | 44,111 | 38,243 | 32,711 | 26,349 | 24,881 |
Loss from operations | ||||||
-34,620 | -24,188 | -18,053 | -16,105 | -20,045 | -9,161 | -13,313 |
Interest and other income, net | ||||||
2,894 | 3,577 | 4,103 | 446 | 1,659 | 869 | 820 |
Income tax benefit | ||||||
-300 | - | - | - | - | - | - |
Net loss | ||||||
-31,403 | -20,611 | -13,950 | -15,659 | -18,386 | -8,292 | -12,493 |
Fair value adjustment to Series E-1 convertible preferred stock options | ||||||
- | 0 | 0 | 710 | 254 | 4 | 2 |
Net loss attributable to common shareholders | ||||||
-31,403 | -20,611 | -13,950 | -16,369 | -18,640 | -8,296 | -12,495 |
Net loss per share attributable to common shareholders, basic and diluted | ||||||
-0.25 | 1.78 | -0.11 | -1.23 | -1.45 | -0.66 | -1.01 |
Weighted-average shares used in computing net loss per share attributable to common shareholders, basic and diluted | ||||||
126,058 | 126,210 | 124,285 | 13,279 | 12,886 | 12,620 | 12,385 |
Sequencing Revenue | ||||||
Total revenue | ||||||
9,469 | 13,888 | 11,683 | 11,865 | 6,083 | 8,463 | 8,281 |
Development Revenue | ||||||
Total revenue | ||||||
11,441 | 10,321 | 14,375 | 10,273 | 6,583 | 8,725 | 3,287 |